Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.60 |
| ▸ | ERBB2 | P04626 | 10/20 | 0.60 |
| ▸ | JAK3 | P52333 | 1/20 | 0.53 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1418468 | 1.00 | EGFR (0.60) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL1419030 | 0.94 | EGFR (0.59) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL1419026 | 0.94 | EGFR (0.59) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL1418063 | 0.88 | EGFR (0.62) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL1418061 | 0.88 | EGFR (0.62) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL1418997 | 0.87 | EGFR (0.65) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL1418995 | 0.87 | EGFR (0.65) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL1419025 | 0.86 | EGFR (0.62) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL1419028 | 0.86 | EGFR (0.62) | EGFRERBB2JAK3ERBB4 | |
| SCHEMBL1418182 | 0.86 | EGFR (0.62) | EGFRERBB2JAK3ERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298746-A1 | 4-amino- quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-03-23 | — | — | EP | claimed |
| US-6972288-B1 | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-12-06 | — | — | US | claimed |
| EP-2298746-A1 | 4-amino- quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2011-03-23 | — | — | EP | disclosed |
| US-6972288-B1 | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-12-06 | — | — | US | disclosed |
| EP-1157011-A1 | 4-AMINO- QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANSDUCTION MEDIATED BY TYROSINE KINASES | Boehringer Ingelheim Pharma KG (DE) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000051991-A1 | 4-AMINO-QUINAZOLINE AND QUINOLINE DERIVATIVES HAVING AN INHIBITORY EFFECT ON SIGNAL TRANsSDUCTION MEDIATED BY TYROSINE KINASES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2000-09-08 | — | — | WO | disclosed |